Positive Oral Data on New RECCE 435 Against H. pylori
Filed with ASX · · 5 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
- RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program
- Response to ASX Price and Volume Query
- Positive Data on RECCE 327 Against Neisseria gonorrhoeae
- Further Positive Data on RECCE 327 Against MRSA Superbug
Later from Recce Pharmaceuticals
- Recce Pharmaceuticals Appoints James Graham as CEO
- Recce Pharmaceuticals Receives Innovation Connections Grant
- Positive & Concentration-Dependent Efficacy Against COVID-19
- R327 Phase I Study - Australias CMAX Clinical Facility
- Recce Completes Capital Raising of $27.95m
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals